Artificial Intelligence

AI Summit: The Promise of Computational Biology, James Data Collective, Abraham Atomwise



1 Comment

  • The reason why pharmaceutical companies don't invest in computational biology is because of prohibitive complexity. There's a lot more basic research that needs to be done before the statistical approach replaces trial and error.

Leave a Reply